Aigh Capital Management LLC Scynexis Inc Transaction History

Aigh Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.15 - $3.0 $888,604 - $2.32 Million	-772,700 Reduced 39.99%	1,159,346 $3.48 Million
Q4 2022 Feb 14, 2023	SELL	$1.46 - $2.49 $36,511 - $62,269	-25,008 Reduced 1.28%	1,932,046 $3.01 Million
Q3 2022 Nov 10, 2022	SELL	$1.83 - $2.93 $514,380 - $823,570	-281,082 Reduced 12.56%	1,957,054 $4.7 Million
Q1 2022 May 12, 2022	BUY	$3.56 - $6.66 $388,363 - $726,546	109,091 Added 5.12%	2,238,136 $8.75 Million
Q4 2021 Feb 10, 2022	BUY	$4.94 - $7.69 $8.82 Million - $13.7 Million	1,785,919 Added 520.48%	2,129,045 $13 Million

Q3 2021 Nov 12, 2021	SELL	$5.3 - $7.89 $6.01 Million - $8.95 Million	-1,133,735 Reduced 76.77%	343,126 $1.82 Million
Q2 2021 Aug 12, 2021	BUY	$6.5 - $9.97 $9.6 Million - $14.7 Million	1,476,861 New	1,476,861 $10.9 Million

15.4M

12.9K

Ticker SCYX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 32,651,800
Market Cap $63.7M
Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...

Get notified when there are updates to the investment portfolio of Aigh Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aigh Capital Management LLC with notifications on news.